These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
448 related items for PubMed ID: 21924648
1. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer. Shi X, Zhang X, Li J, Guo F, Hu Z, Jing Y, Bai L, Chen S, Wan P, Wang F, Gao J, Tan W. Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648 [Abstract] [Full Text] [Related]
2. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, Tan W. J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013 [Abstract] [Full Text] [Related]
3. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine. Wang CY, Hua R, Liu L, Zhan X, Chen S, Quan S, Chu QJ, Zhu YT. Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361 [Abstract] [Full Text] [Related]
4. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells. Zhang X, Shi X, Li J, Hu Z, Guo F, Huang X, Zhang Z, Sun P, Jing Y, Gao J, Tan W. Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685 [Abstract] [Full Text] [Related]
5. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer. Zhu YT, Zhao Z, Fu XY, Luo Y, Lei CY, Chen W, Li F, Pang SY, Chen SS, Tan WL. Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290 [Abstract] [Full Text] [Related]
6. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice]. Peng J, Shi X, Chen D, Liang Z, Lan K, Gao J, Tan W. Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059 [Abstract] [Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H. Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [Abstract] [Full Text] [Related]
11. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine. Shi X, Zhang X, Li J, Mo L, Zhao H, Zhu Y, Hu Z, Gao J, Tan W. Int J Cancer; 2018 May 15; 142(10):2106-2117. PubMed ID: 29243219 [Abstract] [Full Text] [Related]
12. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Chen SA, Tsai MH, Wu FT, Hsiang A, Chen YL, Lei HY, Tzai TS, Leung HW, Jin YT, Hsieh CL, Hwang LH, Lai MD. Clin Cancer Res; 2000 Nov 15; 6(11):4381-8. PubMed ID: 11106257 [Abstract] [Full Text] [Related]
13. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. Yin W, He Q, Hu Z, Chen Z, Qifeng M, Zhichun S, Zhihui Q, Xiaoxia N, Li J, Gao J. Vaccine; 2010 Jul 12; 28(31):4937-44. PubMed ID: 20653081 [Abstract] [Full Text] [Related]